34,500.00

Content Details
Information on this page was last modified on : 2021/05/10 12:11:51 PM

Ristova Injection 100 mg 2 Vialx10 mL

Belongs to Category,

Ristova Injection contains Rituximab | belongs to Monoclonal antibody

Alternate brands of Ristova Injection 100 mg 2 Vialx10 mL

Brand Name Price Savings
Ristova Injection 500 mg 1 Vialx50 mL  85,500.00 You will pay -51000 more
Mabthera Injection 500 mg 1 Vialx50 mL  114,000.00 You will pay -79500 more
Mabthera Injection 100 mg 2 Vialx10 mL  46,000.00 You will pay -11500 more
List of alternate brands

How it works

Ristova Injection 100 mg 2 Vialx10 mL prevents the growth and spread of cancer cells in the body.

Side effects

Major & minor side effects for Ristova Injection 100 mg 2 Vialx10 mL

  • Low blood pressure
  • Nausea and Vomiting
  • Chills and fever
  • Abdominal pain
  • Decrease in white blood cells and platelets
  • Itching
  • Infections severe
  • Headache
  • Muscle aches and pain
  • Cough

Uses of Ristova Injection 100 mg 2 Vialx10 mL

What is it prescribed for?

  • Non-Hodgkin's Lymphoma

    This medicine is used in the treatment of non-Hodgkin's lymphoma, a type of cancer that affects certain cells (lymphocytes) of the lymphatic system.

  • Chronic Lymphocytic Leukaemia

    This medicine is used in the treatment of chronic lymphocytic leukemia, a type of blood cancer.

  • Rheumatoid Arthritis

    This medicine is used in the treatment of Rheumatoid Arthritis, a chronic condition that can affect many joints.

  • Granulomatosis with polyangiitis and microscopic polyangiitis

    This medicine is used in a combination with other medicines for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis, chronic conditions that affect the blood vessels and may cause damage to the organs.

Concerns

Frequently asked questions

  • Onset of action

    The initial response to this medicine can be observed within 7 to 14 days of administration.

  • Duration of Effect

    The effect of this medicine can be detected for up to 6 months after completion of the treatment.

  • Safe with Alchohol?

    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

  • Is it habit forming?

    No habit-forming tendencies were reported.

  • Usage in pregnancy?

    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

  • Usage while breast-feeding?

    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

When not to use?

  • Allergy

    This medicine is not recommended for use in patients with a known allergy to Ristova Injection 100 mg 2 Vialx10 mL , any murine proteins, or any other inactive ingredients present along with it.

  • Active infections

    This medicine is not recommended for use in patients suffering from active, severe infections due to the increased risk of worsening of the patient's condition.

  • Severe immunocompromise

    This medicine is not recommended for use in patients with severe immunocompromise since it may worsen the patient's condition.

Warnings

Warnings for special population
  • Pregnancy

    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

  • Breast-feeding

    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

General Warnings
  • Infusion related reactions

    This medicine has been associated with severe infusion-related reactions, characterized by symptoms such as fever, chills, rigors, low blood pressure, hives, swelling, etc. The onset of these reactions usually ranges from 30 minutes to 2 hours after starting the first intravenous infusion. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.

  • Infections

    This medicine should be used with caution due to the increased risk of severe and potentially life-threatening infections. Report any unusual symptoms such as a fever, diarrhea, sore throat, pain or burning during urination, etc. to the doctor immediately. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases.

Dosage

  • Missed Dose

    This medicine should be used with caution due to the increased risk of severe and potentially life-threatening infections. Report any unusual symptoms such as a fever, diarrhea, sore throat, pain or burning during urination, etc. to the doctor immediately. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases.

  • Overdose

    Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.

Interactions

Interaction with Medicines
  • Live attenuated vaccines and related products severe
  • Adalimumab severe
  • Topotecan moderate
Disease interactions
  • severe

    This medicine should be used with extreme caution in patients suffering from autoimmune disorders due to the increased risk of progressive multifocal leukoencephalopathy (PML) and death. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

  • severe

    This medicine should be used with extreme caution in patients suffering from diseases of the heart due to the increased risk of worsening of the patient's condition. Close monitoring of heart function and vital signs is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

  • severe

    This medicine should be used with extreme caution in patients with a history of Hepatitis B infection due to the increased risk of recurrent outbreaks and worsening of the patient's condition. Close monitoring of clinical condition, appropriate corrective measures, and replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

  • severe

    This medicine should be used with extreme caution due to the increased risk of tumor lysis syndrome. This risk is especially higher in patients suffering from electrolyte abnormalities and kidney diseases. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition off the patient.

  • moderate

    This medicine should be used with extreme caution in patients with a known history of bone marrow suppression since it may worsen the patient's condition. Close monitoring of complete blood cell counts is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

  • moderate

    This medicine should be used with caution in patients with a history of kidney diseases due to the increased risk of serious adverse effects. Close monitoring of kidney function tests is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

General Instructions

This medicine is usually administered by a qualified healthcare professional in the hospital or clinical setting. Inform the doctor if you have a known history of allergy to this medicine. Report to the doctor all your current medicines including any herbs and supplements as well as your medical conditions before receiving this medicine. Report any unusual and significant side effects to the doctor immediately.

Other details

  • Usage does not depend on food timings
  • To be taken as instructed by doctor
  • May cause sleepiness

References

Additional Information:

How to use Ristova Injection 100 mg 2 Vialx10 mL

Do not administer as an IV push or bolus. Interrupt rituximab infusion for severe reactions and resume at a 50% reduction in rate (e.g. from 100 to 50 mg/hours) when symptom have completely resolved. In most cases, patients who have experienced nonlife-threatening reactions have been able to complete the full course of therapy.
Reconstitution: Withdraw necessary amount of rituximab and dilute to final conc. of 1-4 mg /mL into an infusion bag containing either NS or D5W.
Stability: Store under refrigeration. Protect vials from direct sunlight. Solution for infusion is stable at 2°C-8°C for 24 hours and at room temperature for an additional 12 hours.

what are the adverse effects of Ristova Injection 100 mg 2 Vialx10 mL?

Headache, fever, chills, nausea, leucopenia, hypotension, dizziness, pruritus, rash, neutropenia, thrombocytopenia, anaemia, rhinitis, diarrhoea, dyspepsia, anorexia, agitation, insomnia, nervousness, cough, bronchitis, sweating, severe vision loss, hearing loss, loss of other senses, HTN, hypotension, hypercholesterolaemia, migraine, UTI.

What happens if I miss a dose of Ristova Injection 100 mg 2 Vialx10 mL?

Adults: Follicular lymphoma as single agent: 375 mg/m² by IV infusion once weekly for 4 wk.
Follicular lymphoma with CVP: 375 mg/m² by IV infusion for 8 cycles on Day 1 of each chemotherapy cycle after corticosteroid component of CVP.
Large B-cell lymphoma: 375 mg/m² by IV infusion on Day 1 of each chemotherapy cycle for 8 cycles after corticosteroid component of CHOP. See literature.

One of the following licensed pharmacy from the nearest location will deliver Ristova Injection 100 mg 2 Vialx10 mL. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.

Want to share this information?
Facebook
Twitter
LinkedIn
Something doesn't feel right ?

Questions and Answers

There are no questions yet. Be the first to ask a question about this product.

Only registered users are eligible to enter questions

Reviews

There are no reviews yet.

Be the first to review “Ristova Injection 100 mg 2 Vialx10 mL”
Shopping Cart